Related references
Note: Only part of the references are listed.Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease A Cohort Study
Monique K. van der Kooij et al.
ANNALS OF INTERNAL MEDICINE (2021)
Risk factors for immune mediated adverse events with immune checkpoint inhibitors.
Ari Pelcovits et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Tawnie J. Braaten et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Trends in clinical development for PD-1/PD-L1 inhibitors
Jia Xin Yu et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective study
R. Dupont et al.
ONCOIMMUNOLOGY (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
J. Haanen et al.
ANNALS OF ONCOLOGY (2020)
Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities
Yves Allenbach et al.
AUTOIMMUNITY REVIEWS (2020)
Risk of scleroderma according to the type of immune checkpoint inhibitors
Benjamin Terrier et al.
AUTOIMMUNITY REVIEWS (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy
Keisuke Yokohama et al.
SCIENTIFIC REPORTS (2020)
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
Bairavi Shankar et al.
JAMA ONCOLOGY (2020)
Lower risk of severe checkpoint inhibitor toxicity in more advanced disease
Rik J. Verheijden et al.
ESMO OPEN (2020)
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini et al.
ONCOLOGIST (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study
Alice Tison et al.
ARTHRITIS & RHEUMATOLOGY (2019)
58P Risk factors for immune related adverse events: A retrospective study
A Q Parmanande et al.
ANNALS OF ONCOLOGY (2019)
Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab
Yeonghee Eun et al.
SCIENTIFIC REPORTS (2019)
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
Biagio Ricciuti et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma
Alice Indini et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the French Pharmacovigilance database
Julie Garon-Czmil et al.
SCIENTIFIC REPORTS (2019)
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
Francois-Xavier Danlos et al.
EUROPEAN JOURNAL OF CANCER (2018)
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
Giulia C. Leonardi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Rheumatic immune-related adverse events from cancer immunotherapy
Leonard H. Calabrese et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
A. M. Menzies et al.
ANNALS OF ONCOLOGY (2017)
Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity
Ralf Gutzmer et al.
EUROPEAN JOURNAL OF CANCER (2017)
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies
M. Collins et al.
ANNALS OF ONCOLOGY (2017)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options
Saad A. Khan et al.
JAMA ONCOLOGY (2016)
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitorsaEuro
T. W. Chen et al.
ANNALS OF ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Updated assessment of the prevalence, spectrum and case definition of autoimmune disease
Scott M. Hayter et al.
AUTOIMMUNITY REVIEWS (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Share Paper
